Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure

This invention is directed to methods and compositions of teating acute or chronic renal failure or dysfunction, or conditions caused thereby comprising administering prostaglandin agonists, which ae EP4 receptor selective prostaglandin agonists.

Saved in:
Bibliographic Details
Main Authors VISHWAS MADHAV PARALKAR, DAVID DUANE THOMPSON
Format Patent
LanguageEnglish
Published 01.07.2004
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention is directed to methods and compositions of teating acute or chronic renal failure or dysfunction, or conditions caused thereby comprising administering prostaglandin agonists, which ae EP4 receptor selective prostaglandin agonists.
Bibliography:Application Number: AU20010016722